clinical research

Thanks for being observed

Graham Stocks — Thu, 24 Nov 2011 19:37:38 -0800

The Australian HIV Observational Database (AHOD) is an important monitor of trends in an iretroviral patterns and emerging health issues within the HIV community.

New trial needs volunteers

Graham Stocks — Wed, 23 Nov 2011 20:08:39 -0800

At the conference, Julian Elliot from The Burnet Institute in Melbourne spoke of our ‘combo-prevention future’, where a successful vaccine and cure could potentially end the epidemic.

Serodiscordant study

Graham Stocks — Thu, 10 Jun 2010 19:01:09 -0700

While it has long been acknowledged that successful antiretroviralA medication or other substance which is active against retroviruses such as HIV. treatment and an undetectable viral loadA measurement of the quantity of HIV RNA in the blood. Viral load blood test results are expressed as the number of copies (of HIV) per milliliter of blood plasma. lowers the risk of passing on HIV, we have little research to support the fact.

Microbicide and vaccine both hit snags

Graham Stocks — Wed, 03 Mar 2010 21:15:30 -0800

PRO 2000, the microbicide gel, has failed to protect women against HIV infection in the largest microbicide study to date.

CROI 2010: All that's new in HIV

Graham Stocks — Wed, 03 Mar 2010 14:50:23 -0800

The Conference on Retroviruses and Opportunistic Infections (CROI) has just happened in San Francisco. This meeting is held annually and focuses on the very latest in basic science and clinicalPertaining to or founded on observation and treatment of participants, as distinguished from theoretical or basic science. research. Jo Watson was there and gives us an overview.

Second Line treatment trial begins

Graham Stocks — Thu, 03 Dec 2009 14:31:14 -0800

A treatment regimen consisting of one nonnucleoside (1NNRTI) and two nucleosides (2NRTIs) has become the internationally accepted first-line therapy of choice. But effective as the combination is, it doesn’t work for everyone. And those it fails need a reliable back-up.

HIV Seroconversion Study 2007 - 9

Scott Lockhart — Sun, 18 Oct 2009 21:54:55 -0700

The Seroconversion Study collects both quantitative and qualitative data from mainly homosexual men who have recently been diagnosed with HIV. Men are referred to the online questionaire through clinics and HIV organisations providing services to men who are newly diagnosed. Men completing the online questionaire volunteer for the more extended depth interview.

Bone health and HIV

Jill Sergeant — Thu, 04 Jun 2009 23:13:43 -0700

Those of us with HIV are more likely to have conditions such as osteopenia (low bone mineral density) and osteoporosis (weakened bones) than our negative contemporaries.

New trial to determine if better to start treatment earlier

Jill Sergeant — Thu, 04 Jun 2009 22:41:33 -0700

An international trial that has just started enrollingThe act of signing up participants into a study. Generally this process involves evaluating a participant with respect to the eligibility criteria of the study and going through the informed consent process. in Australia aims to determine whether it is better to start treatment earlier, when T-cell counts are above 500, or when they drop to 350 as per the current recommendations.

Lower dosing trial funded

Jill Sergeant — Thu, 04 Jun 2009 22:22:46 -0700

The Bill and Melinda Gates Foundation has granted AUD $12.4 million to the University of NSW to study whether lower doses of some commonly used antiretroviralA medication or other substance which is active against retroviruses such as HIV. drugs are as effective as currently prescribed doses.